Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

OptiBiotix to showcase industry-leading technology at top conference next month

The poster and verbal exposition will focus on OptiBiotix's ability to identify and develop targeted prebiotics
gut schematic
The gut is host to a whole ecosystem of bacteria which helps promote good health

OptiBiotix Health plc’s (LON:OPTI) work on the emerging field of the human microbiome will be recognised at a leading industry conference next month.

For the company is to present an abstract at ProBiota 2018, attended by the movers and shakers of the industry.

READ: Optibiotix Health eyes up future projects

The poster and verbal exposition will focus on OptiBiotix's ability to identify and develop targeted prebiotics which can enhance the growth rate and health benefits of specific microbial species. In doing so they aid the efficacy of probiotic products.

Deeper dive

To understand what this means it is worth going back to first principles. As mentioned, the company’s focus is the human microbiome, an ecosystem of bacteria and yeasts that reside in the gut and on the skin.

It is thought changes to the human flora can have an impact on health, hence the proliferation of functional foods such as yoghurts filled with probiotic, or good bacteria.

OptiBiotix’s focus is mainly on the gut with advances designed to tackle obesity, cholesterol and diabetes although the company does have a separately-quoted business developing skincare products.

What it is showcasing at the ProBiota conference is a prebiotic which helps promote the growth of the health-giving micro-organisms such as Lactobacillus rhamnosus GG, or LGG for short.

This new product concept utilises OptiBiotix's synbiotics technology and has the potential to enhance probiotic health benefits and provide a product that is different to the current me-too offerings.

Designer prebiotics

“The ability to create designer prebiotics which can selectively modulate the growth of an individual species and be used in combination to improve the efficacy of existing probiotics, or by itself to modify an individual's microbiome to improve health, is a hugely exciting development in global microbiome research and product development,” said OptiBiotix chief executive Stephen O’Hara.

“We believe we are fast approaching a future where microbiome products will make a significant contribution to the prevention, management and treatment of disease.

“The ability to create designer ingredients which can precision engineer the microbiome to improve health places OptiBiotix at the forefront of this global health trend."

ProBiota 2018 takes place in Barcelona February 7-9.

View full OPTI profile View Profile

OptiBiotix Health plc Timeline

Related Articles

September 27 2018
WideCells has undertaken a review of the business to deliver a strategy that will generate revenue, reduce overheads and achieve profitability
Proton Therapy sign
October 10 2018
The broker says the cancer treatment developer could potentially take the entire share of the growth market from ageing cyclotron companies
July 30 2018
Life science generally is developing at an incredible speed, says Joe Anderson

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use